Ítem
Acceso Abierto
Passive transfer of Plasmodium falciparum MSP-2 pseudopeptide-induced antibodies efficiently controlled parasitemia in Plasmodium berghei-infected mice
Título de la revista
Autores
Martínez, Paola A.
Yandar, Nubia
Lesmes, Liliana P.
Forero, Martha
Pérez-Leal, Oscar
Patarroyo, Manuel Elkin
Lozano, José Manuel
Archivos
Fecha
2009
Directores
ISSN de la revista
Título del volumen
Editor
Citations
Métricas alternativas
Resumen
Abstract
We have developed monoclonal antibodies directed against the pseudopeptide ?-130, derived from the highly conserved malarial antigen Plasmodium falciparum merozoite surface protein 2 (MSP-2), for obtaining novel molecular tools with potential applications in the control of malaria. Following isotype switching, these antibodies were tested for their ability to suppress blood-stage parasitemia through passive immunization in malaria-infected mice. Some proved totally effective in suppressing a lethal blood-stage challenge infection and others reduced malarial parasitemia. Protection against P. berghei malaria following Ig passive immunization can be associated with specific immunoglobulins induced by a site-directed designed MSP-2 reduced amide pseudopeptide. © 2008 Elsevier Inc. All rights reserved.
Palabras clave
Keywords
Immunoglobulin , Immunoglobulin class , Malaria vaccine , Merozoite surface protein 2 , Monoclonal antibody , Monoclonal antibody anti pseudopeptide psi 130 , Pseudopeptide , Unclassified drug , Animal cell , Animal experiment , Animal model , Animal tissue , Article , Controlled study , Drug design , Drug mechanism , Drug synthesis , Female , Mouse , Nonhuman , Parasitemia , Passive immunization , Plasmodium berghei infection , Plasmodium falciparum , Priority journal , Animals , Antibodies, protozoan , Antigens, protozoan , Disease models, animal , Female , Immunization, passive , Malaria , Mice , Mice, inbred balb c , Parasitemia , Plasmodium berghei , Plasmodium falciparum , Protozoan proteins , Recombinant proteins , Murinae , Mus , Plasmodium berghei , Plasmodium falciparum , Anti-malarial vaccine , Ig isotype , In vivo neutralizing activity , Murine malarial infection , Pseudopeptide
